Dishman Carbogen Amcis reports Rs 124.61 crore H1FY27 loss
Key highlights
- Dishman Carbogen Amcis recorded a Rs 124.61 crore loss after tax in H1FY27, versus a Rs 88.68 crore profit in H1FY26.
- H1FY27 operating revenue declined 12.9% to Rs 1,185.01 crore, led by a 17.1% fall in CDMO revenue.
- H1FY27 EBITDA margin fell to 8.9% from 21.3%, while EBITDA declined 63.4% to Rs 106.04 crore.
- Project deliverables worth approximately CHF 10 million were rescheduled from H1FY27 to H2FY27.
powered by IRIS

Dishman Carbogen Amcis Limited recorded a Rs 124.61 crore consolidated loss after tax in H1FY27, compared with a Rs 88.68 crore profit in H1FY26, as revenue fell 12.9% and EBITDA margin declined to 8.9% from 21.3%. The result reflected lower Contract Development and Manufacturing Organisation (CDMO) revenue, deferred project deliverables and lower fixed-cost absorption.
Know Dishman Carbogen Amcis inside out
Results, valuation, peers and who's buying, in one view.
Why did Dishman Carbogen Amcis report a loss in H1FY27?
Dishman Carbogen Amcis reported a loss because operating profit fell sharply while depreciation and finance costs remained substantial. EBITDA, or earnings before interest, tax, depreciation and amortisation, declined 63.4% year on year to Rs 106.04 crore in H1FY27 from Rs 289.57 crore in H1FY26. The EBITDA margin contracted by 12.4 percentage points to 8.9%.
Below EBITDA, depreciation and amortisation rose 9.4% to Rs 181.10 crore in H1FY27, exceeding the period's operating profit. Finance cost, including foreign-exchange impact, was Rs 77.19 crore, although it declined 9.3% from Rs 85.09 crore a year earlier. Profit before tax consequently moved to a Rs 132.22 crore loss from a Rs 69.21 crore profit, before a Rs 7.61 crore tax credit resulted in the Rs 124.61 crore loss after tax.
How much did Dishman Carbogen Amcis revenue and profit change?
Dishman Carbogen Amcis generated Rs 1,185.01 crore of H1FY27 operating revenue, down from Rs 1,360.70 crore in H1FY26, with its larger CDMO segment accounting for the reduction. CDMO revenue decreased by Rs 191.60 crore to Rs 929.04 crore, while Marketable Molecules revenue increased by Rs 15.91 crore to Rs 255.97 crore.
The second quarter showed a steeper revenue decline than the half year. Q2FY27 revenue was Rs 507.37 crore, 22.3% below Rs 652.65 crore in Q2FY26, while EBITDA fell 69.1% to Rs 45.96 crore. Q2FY27 CDMO revenue was Rs 388.75 crore, down from Rs 509.40 crore, and Marketable Molecules revenue declined to Rs 118.62 crore from Rs 143.25 crore.
What caused Dishman Carbogen Amcis margin contraction?
Dishman Carbogen Amcis attributed the H1FY27 margin decline primarily to lower revenue, particularly in CDMO, against its fixed cost base. The company said CDMO revenue fell because development revenue was lower and project deliverables worth approximately CHF 10 million were rescheduled to H2FY27. CDMO represented 78% of H1FY27 operating revenue, making its shortfall material to consolidated profitability.
CDMO's H1FY27 EBITDA margin fell to 8.7% from 21.3% in H1FY26. In Q2FY27, its margin was 12.3%, compared with 25.3% in Q2FY26. Employee expenses increased 3.8% year on year to Rs 710.72 crore during the half year even as revenue declined, while cost of goods sold rose 12.5% to Rs 149.01 crore. Other expenses fell 13.6% to Rs 219.24 crore but did not offset the revenue reduction.
Marketable Molecules provided revenue growth but did not retain its earlier segment margin. Its H1FY27 EBITDA margin was 9.7%, down from 21.4% in H1FY26, as sales carried a higher contribution from lower-margin cholesterol products and Quaternary compounds relative to Vitamin D analogues. The company said higher Quaternary compounds sales supported the 6.6% half-year revenue increase, while lower vitamin-segment revenue contributed to a 17.9% quarter-on-quarter decline cited for H1FY27.
Got a follow-up? Ask IRIS
What does Dishman Carbogen Amcis disclose about its financial position?
Dishman Carbogen Amcis reported Rs 1,179.61 crore of total assets at September 2026, down from Rs 1,192.33 crore at March 2026. Current assets increased to Rs 301.38 crore from Rs 284.21 crore, including cash and cash equivalents of Rs 100.91 crore versus Rs 78.78 crore. Trade receivables declined to Rs 47.04 crore from Rs 67.29 crore, while inventories increased to Rs 111.28 crore from Rs 101.91 crore.
Borrowings shifted toward the current category at September 2026. Long-term borrowings were broadly unchanged at Rs 153.18 crore, against Rs 153.49 crore in March 2026, but short-term borrowings increased to Rs 163.19 crore from Rs 124.05 crore. Total shareholder funds were Rs 667.11 crore at September 2026, compared with Rs 667.69 crore at March 2026, according to the reported consolidated balance sheet.
Capital work in progress stood at Rs 29.19 crore at September 2026, compared with Rs 27.50 crore at March 2026. Property, plant and equipment declined to Rs 280.99 crore from Rs 294.19 crore over the same period, while intangible assets under development increased to Rs 32.37 crore from Rs 29.53 crore. The company also reported cash and cash equivalents of Rs 100.91 crore at September 2026.
Conclusion
The H1FY27 result shows that revenue timing and segment mix materially affected Dishman Carbogen Amcis's earnings. The Rs 191.60 crore year-on-year reduction in CDMO revenue outweighed the Rs 15.91 crore increase in Marketable Molecules revenue, while fixed costs and higher depreciation contributed to the movement from a Rs 88.68 crore profit to a Rs 124.61 crore loss.
The disclosed item to watch is the movement of approximately CHF 10 million of rescheduled CDMO project deliverables into H2FY27. The second half will also indicate whether development revenue improves and whether the sales mix among cholesterol products, Quaternary compounds and Vitamin D analogues changes the Marketable Molecules segment's 9.7% H1FY27 EBITDA margin.


